new scrutiny of pharmacy compounding

December 2012

The fungal meningitis outbreak in the U.S. will result in new scrutiny of pharmacy compounding.

We all know that compounding fills several important needs.

But it gets confusing when a compounder acts like a manufacturer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology whether ALL patients with coronary artery disease should take a beta-blocker
Anticoagulants change in the brand name for dabigatran from Pradax to Pradaxa
Anticoagulants more about bleeding with Pradaxa (dabigatran)
Practice misleading claims about the Hemocode test for food intolerance
Diabetes debate about whether diabetes patients who don't use insulin benefit from monitoring their blood glucose
Diabetes two new tablet strengths of Januvia (sitagliptin)
Gout rev up promotion of Uloric (febuxostat) for managing gout
Compounding new scrutiny of pharmacy compounding
Vaccines New recommendations will bring more focus on proper vaccine storage
Fibromyalgia Canadian guidelines will help improve fibromyalgia treatment
Interactions PPIs with methotrexate can lead to methotrexate toxicity
Practice we hope you'll enjoy the holiday letter from our staff